BR112015023910A2 - terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer - Google Patents

terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer

Info

Publication number
BR112015023910A2
BR112015023910A2 BR112015023910A BR112015023910A BR112015023910A2 BR 112015023910 A2 BR112015023910 A2 BR 112015023910A2 BR 112015023910 A BR112015023910 A BR 112015023910A BR 112015023910 A BR112015023910 A BR 112015023910A BR 112015023910 A2 BR112015023910 A2 BR 112015023910A2
Authority
BR
Brazil
Prior art keywords
claudin
antibody
cancer treatment
cancer
data
Prior art date
Application number
BR112015023910A
Other languages
English (en)
Other versions
BR112015023910B1 (pt
Inventor
Sahin Ugur
Türeci Özlem
Original Assignee
Ganymed Pharmaceuticals Ag
Tron -Translationale Onkologie An Der Univ Der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag, Tron -Translationale Onkologie An Der Univ Der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gm filed Critical Ganymed Pharmaceuticals Ag
Publication of BR112015023910A2 publication Critical patent/BR112015023910A2/pt
Publication of BR112015023910B1 publication Critical patent/BR112015023910B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo de patente de invenção para: “terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer”. a presente invenção, de uma forma geral, proporciona uma terapia eficaz para o tratamento e / ou prevenção de doenças associadas com células que expressam cldn 18,2, em particular, doenças cancerosas, tais como o câncer gastro-esofágico. os dados são apresentados demonstrando que a administração de um anticorpo anti-cldn18.2 a pacientes humanos com câncer gastroesofágico é segura e bem tolerada até uma dose de pelo menos 1.000 mg / m2. além disso, os dados são apresentados demonstrando que o anticorpo é totalmente funcional nestes pacientes para executar efeitos em células anti-tumorais e evidência de atividade anti-tumoral foi obtida
BR112015023910A 2013-03-18 2014-03-17 terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer BR112015023910B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/000817 WO2014146672A1 (en) 2013-03-18 2013-03-18 Therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2014/000719 WO2014146778A1 (en) 2013-03-18 2014-03-17 Therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (2)

Publication Number Publication Date
BR112015023910A2 true BR112015023910A2 (pt) 2017-03-21
BR112015023910B1 BR112015023910B1 (pt) 2019-09-10

Family

ID=48182875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023910A BR112015023910B1 (pt) 2013-03-18 2014-03-17 terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer

Country Status (19)

Country Link
US (3) US10137195B2 (pt)
JP (5) JP6416197B2 (pt)
KR (2) KR20230015514A (pt)
CN (1) CN105189554B (pt)
AU (4) AU2014234684B2 (pt)
BR (1) BR112015023910B1 (pt)
CA (1) CA2899770A1 (pt)
DK (1) DK2976360T3 (pt)
ES (1) ES2765949T3 (pt)
HK (1) HK1219486A1 (pt)
HU (1) HUE048541T2 (pt)
IL (3) IL299004B2 (pt)
MX (2) MX2015013355A (pt)
MY (1) MY191040A (pt)
PT (1) PT2976360T (pt)
RU (2) RU2019101923A (pt)
SG (2) SG10201707684WA (pt)
UA (1) UA119036C2 (pt)
WO (2) WO2014146672A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
SG11201503593UA (en) 2012-11-13 2015-06-29 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165765A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
SG11201900171QA (en) * 2016-07-08 2019-02-27 Carsgen Therapeutics Co Ltd Antibody for anti-claudin 18a2 and use thereof
AU2019232762B2 (en) * 2018-03-08 2023-11-16 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
CN111788228B (zh) * 2018-05-18 2023-04-14 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
CN111867630B (zh) 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
CN112512581A (zh) * 2018-08-03 2021-03-16 安进研发（慕尼黑）股份有限公司 针对cldn18.2和cd3的抗体构建体
TW202023613A (zh) * 2018-08-27 2020-07-01 大陸商南京聖和藥業股份有限公司 一種抗Claudin18_2抗體及其應用
WO2020063988A1 (zh) * 2018-09-30 2020-04-02 科济生物医药（上海）有限公司 Cldn18的抗体和化疗药物的联合治疗
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
KR20210109520A (ko) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
KR20220024010A (ko) * 2019-05-16 2022-03-03 치루 파머수티컬 컴퍼니 리미티드 클라우딘 18a2에 대한 항체 및 그의 용도
CN117659190A (zh) * 2019-05-16 2024-03-08 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
CA3141504A1 (en) * 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
US20220204609A1 (en) * 2019-05-30 2022-06-30 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
WO2021011885A1 (en) * 2019-07-17 2021-01-21 The Regents Of The University Of California Claudin18 antibodies and methods of treating cancer
CN113166265B (zh) * 2019-08-12 2024-06-04 天境生物科技(上海)有限公司 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途
CN114630840A (zh) * 2019-08-20 2022-06-14 苏州创胜医药集团有限公司 新型抗cldn18.2抗体
TW202124442A (zh) * 2019-09-13 2021-07-01 大陸商北京軒義醫藥科技有限公司 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
CN112707965A (zh) 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
JP2023505318A (ja) * 2019-12-06 2023-02-08 ソティオ バイオテック エイ．エス． ヒト化ｃｌｄｎ１８．２抗体
WO2021239026A1 (zh) * 2020-05-29 2021-12-02 杭州邦顺制药有限公司 针对Claudin18.2的抗体及其用途
CA3184342A1 (en) * 2020-06-23 2021-12-30 Antengene Biologics Limited Antibodies and methods for treating claudin-associated diseases
CN111777681B (zh) * 2020-07-06 2022-10-11 康诺亚生物医药科技（成都）有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
WO2022100590A1 (zh) * 2020-11-10 2022-05-19 齐鲁制药有限公司 针对密蛋白18a2的adcc增强型人源化抗体及其应用
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
AU2022326063A1 (en) 2021-08-09 2024-03-14 Harbour Biomed (Shanghai) Co., Ltd Cldn18.2-targeting antibody, bispecific antibody and use thereof
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN117701719B (zh) * 2024-02-04 2024-05-31 北京肿瘤医院(北京大学肿瘤医院) 肿瘤靶向cldn18.2治疗耐药标志物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
EP1144629A3 (en) 1998-09-01 2001-11-28 Genentech, Inc. Further pro polypeptides and sequences thereof
EP1112364A2 (en) 1998-09-16 2001-07-04 ZymoGenetics, Inc. Stomach polypeptide zsig28
WO2000020447A2 (en) 1998-10-06 2000-04-13 Curagen Corporation Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
AU3774500A (en) 1999-03-31 2000-10-16 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1254219A2 (en) 2000-01-31 2002-11-06 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055321A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1251863A4 (en) 2000-01-31 2005-03-02 Human Genome Sciences Inc 22 SEPARATE HUMAN PROTEINS
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001090357A1 (en) 2000-05-24 2001-11-29 Genesis Research & Development Corporation Limited Compositions isolated from skin cells and methods for their use
ATE363531T1 (de) 2000-08-15 2007-06-15 Immunex Corp Claudin polypeptide
AU2001286810A1 (en) 2000-08-28 2002-03-13 Diadexus, Inc. Compositions and methods relating to lung specific genes
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP1929003A4 (en) 2005-08-31 2009-04-29 Cell Signaling Technology Inc REAGENTS FOR DETECTION OF PROTEIN PHOSPORYLATION IN CARCINOMA SIGNALING PATHWAYS
DK1934615T3 (da) 2005-09-19 2014-07-14 Janssen Diagnostics Llc Fremgangsmåder og materialer til identificering af oprindelsen af et karcinom med ukendt primær oprindelse
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1981539B1 (en) 2006-02-09 2014-07-23 Amgen Research (Munich) GmbH Treatment of metastatic breast cancer
US20100129929A1 (en) 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
EP2125034A4 (en) 2007-02-01 2010-01-27 Veridex Llc METHODS AND SUBSTANCES FOR IDENTIFYING THE ORIGIN OF AN UNKNOWN UNKNOWN MAIN CARCINOMA
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JPWO2008152822A1 (ja) 2007-06-15 2010-08-26 株式会社メディネット 医薬
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
WO2010141093A2 (en) 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
SG10201707684WA (en) 2017-11-29
JP7018361B2 (ja) 2022-02-10
BR112015023910B1 (pt) 2019-09-10
JP6416197B2 (ja) 2018-10-31
KR102490997B1 (ko) 2023-01-25
IL240060A0 (en) 2015-09-24
US20190076525A1 (en) 2019-03-14
MX2020003719A (es) 2020-07-22
JP2018184403A (ja) 2018-11-22
KR20150130318A (ko) 2015-11-23
IL240060B2 (en) 2023-05-01
JP2024056803A (ja) 2024-04-23
US20220184209A1 (en) 2022-06-16
AU2014234684B2 (en) 2018-12-06
MX2015013355A (es) 2016-06-24
AU2020210165A1 (en) 2020-08-13
WO2014146672A1 (en) 2014-09-25
IL305017A (en) 2023-10-01
JP2022133424A (ja) 2022-09-13
CN105189554A (zh) 2015-12-23
UA119036C2 (uk) 2019-04-25
CN105189554B (zh) 2021-10-08
HUE048541T2 (hu) 2020-07-28
RU2015144666A3 (pt) 2018-03-26
JP2020143153A (ja) 2020-09-10
CA2899770A1 (en) 2014-09-25
WO2014146778A1 (en) 2014-09-25
US20160008465A1 (en) 2016-01-14
DK2976360T3 (da) 2020-01-27
US10137195B2 (en) 2018-11-27
PT2976360T (pt) 2020-01-22
IL299004B1 (en) 2023-10-01
AU2014234684A1 (en) 2015-08-20
RU2015144666A (ru) 2017-04-21
NZ710648A (en) 2021-03-26
ES2765949T3 (es) 2020-06-11
IL299004B2 (en) 2024-02-01
AU2019201513B2 (en) 2020-08-13
JP7166310B2 (ja) 2022-11-07
AU2019201513A1 (en) 2019-03-28
KR20230015514A (ko) 2023-01-31
US11395852B2 (en) 2022-07-26
JP2016517447A (ja) 2016-06-16
ES2765949T8 (es) 2020-06-23
IL240060B1 (en) 2023-01-01
SG11201507764QA (en) 2015-10-29
AU2020210165B2 (en) 2022-07-14
IL299004A (en) 2023-02-01
HK1219486A1 (zh) 2017-04-07
RU2019101923A (ru) 2019-02-22
MY191040A (en) 2022-05-30
AU2022246477A1 (en) 2022-11-03
RU2678700C2 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
BR112016028964A2 (pt) métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B25D Requested change of name of applicant approved

Owner name: TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; GANYMED PHARMACEUTICALS GMBH (DE)

B25A Requested transfer of rights approved

Owner name: TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; ASTELLAS PHARMA INC. (JP)